Literature DB >> 18278805

CYBB, an NADPH-oxidase gene: restricted diversity in humans and evidence for differential long-term purifying selection on transmembrane and cytosolic domains.

Eduardo Tarazona-Santos1, Toralf Bernig, Laurie Burdett, Wagner C S Magalhaes, Cristina Fabbri, Jason Liao, Rodrigo A F Redondo, Robert Welch, Meredith Yeager, Stephen J Chanock.   

Abstract

CYBB encodes the gp91-phox protein of the phagocytic NADPH oxidase; the innate immunity-related enzymatic complex responsible for the respiratory burst. Mutations in CYBB can cause chronic granulomatous disease (CGD), a primary immunodeficiency characterized by ineffective microbicidal activity, for which over 150 family-specific mutations have been described. It is also plausible that common SNPs in CYBB alter the expression or function of gp91-phox, determining differences in susceptibility to complex disorders such as autoimmune or infectious diseases. We have resequenced the exons, UTRs, and intronic regions of CYBB in 102 ethnically diverse individuals and genotyped nine tag-SNPs in 942 individuals from 52 worldwide populations. The 28 observed SNPs (none of which nonsynonymous) reside on 28 haplotypes that can be collapsed into five clades. CYBB shows lower diversity than other X-chromosome genes and most of the between-population genetic variance was observed among Africans and non-Africans. The African population shows the highest diversity and the lowest linkage disequilibrium (LD). Because there is extensive shared LD among non-Africans, tag-SNPs can be effectively employed in gene-centric association studies and are portable across Eurasian and Native American populations. Comparison of CYBB coding sequences among mammals evidences the action of long-term purifying selection, which is stronger on the C-terminal cytosolic domain than on the N-terminal transmembrane domain of gp91-phox.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18278805     DOI: 10.1002/humu.20667

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  6 in total

1.  Phred-Phrap package to analyses tools: a pipeline to facilitate population genetics re-sequencing studies.

Authors:  Moara Machado; Wagner Cs Magalhães; Allan Sene; Bruno Araújo; Alessandra C Faria-Campos; Stephen J Chanock; Leandro Scott; Guilherme Oliveira; Eduardo Tarazona-Santos; Maira R Rodrigues
Journal:  Investig Genet       Date:  2011-02-01

2.  Evolutionary dynamics of the human NADPH oxidase genes CYBB, CYBA, NCF2, and NCF4: functional implications.

Authors:  Eduardo Tarazona-Santos; Moara Machado; Wagner C S Magalhães; Renee Chen; Fernanda Lyon; Laurie Burdett; Andrew Crenshaw; Cristina Fabbri; Latife Pereira; Laelia Pinto; Rodrigo A F Redondo; Ben Sestanovich; Meredith Yeager; Stephen J Chanock
Journal:  Mol Biol Evol       Date:  2013-07-02       Impact factor: 16.240

3.  Diversity in the glucose transporter-4 gene (SLC2A4) in humans reflects the action of natural selection along the old-world primates evolution.

Authors:  Eduardo Tarazona-Santos; Cristina Fabbri; Meredith Yeager; Wagner C Magalhaes; Laurie Burdett; Andrew Crenshaw; Davide Pettener; Stephen J Chanock
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

4.  The expression of Hexokinase 2 and its hub genes are correlated with the prognosis in glioma.

Authors:  Yishan Huang; Fan Ouyang; Fengxia Yang; Ning Zhang; Weijiang Zhao; Hongwu Xu; Xiaojun Yang
Journal:  BMC Cancer       Date:  2022-08-18       Impact factor: 4.638

5.  Identification and validation of MicroRNA-mRNA Networks in Dorsal Root Ganglia after Peripheral Nerve Injury.

Authors:  Xinyi Gu; Hao Guo; Canjun Zeng; Yijun Liu
Journal:  Int J Med Sci       Date:  2022-07-11       Impact factor: 3.642

6.  Genome-wide scan for signatures of human population differentiation and their relationship with natural selection, functional pathways and diseases.

Authors:  Roberto Amato; Michele Pinelli; Antonella Monticelli; Davide Marino; Gennaro Miele; Sergio Cocozza
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.